Sun Pharma Signs Non-Exclusive Patent Licensing Agreement with Takeda for Voltapraz (Vonoprazan) in India
Sun Pharmaceutical Industries Ltd. has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Limited to commercialize Vonoprazan tablets 10 mg, 20 mg in India under the brand name ‘Voltapraz’. Vonoprazan is a novel, orally active potassium competitive acid blocker used to treat reflux esophagitis and other acid peptic disorders. The agreement grants Sun Pharma non-exclusive patent licensing rights for the commercialization of Vonoprazan in India. The drug is approved in India for treatment of adults with Reflux esophagitis and other acid peptic disorders. The prevalence of GERD in the Indian population ranges from 5% to 28.5%, with risk factors including age, body mass index, non-vegetarian diet, tea/coffee intake, tobacco, and alcohol consumption.
Key Highlights
- Sun Pharma has signed a non-exclusive patent licensing agreement with Takeda for Vonoprazan in India.
- Vonoprazan is a novel, orally active potassium competitive acid blocker used to treat reflux esophagitis and other acid peptic disorders.
- The agreement grants Sun Pharma non-exclusive patent licensing rights for the commercialization of Vonoprazan in India.
- Vonoprazan is approved in India for treatment of adults with Reflux esophagitis and other acid peptic disorders.
- The prevalence of GERD in the Indian population ranges from 5% to 28.5%, with risk factors including age, body mass index, non-vegetarian diet, tea/coffee intake, tobacco, and alcohol consumption.